For research use only. Not for use in humans.

Anetumab ravtansine

Synonyms: BAY 94-9343

Anetumab ravtansine (BAY 94-9343) is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. Anetumab ravtansine has the potential to treat advanced solid tumors.

Anetumab ravtansine

CAS No. 1375258-01-7

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 6.72mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Anetumab ravtansine (BAY 94-9343) is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. Anetumab ravtansine has the potential to treat advanced solid tumors.
References

Product Details

CAS No. 1375258-01-7
ADC antiody Anetumab
ADC cytotoxin DM4
Formulation 100 mM Pro-Ac, 20 mM Arg-Ac, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03816358 ACTIVE_NOT_RECRUITING Drug: Gemcitabine Hydrochloride Pancreatic Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 National Cancer Institute (NCI) 2019-12-09 PHASE1
NCT03587311 ACTIVE_NOT_RECRUITING Drug: Paclitaxel Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma National Cancer Institute (NCI) 2018-10-12 PHASE2
NCT03126630 ACTIVE_NOT_RECRUITING Pleural Malignant Mesothelioma National Cancer Institute (NCI) 2018-10-04 PHASE1; PHASE2
NCT03926143 TERMINATED Drug: BAY94-9343 (Anetumab ravtansine) Solid Tumors Bayer 2019-06-03 PHASE2
NCT03102320 COMPLETED Drug: Cisplatin|Drug: Gemcitabine|Drug: Anetumab ravtansine Neoplasms Bayer 2017-05-26 PHASE1
NCT03455556 TERMINATED Mesothelin Positive; Stage III Non-Small Cell Lung Cancer AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Non-Small Cell Lung Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7 Mayo Clinic 2018-08-10 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-21)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.